<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028231</url>
  </required_header>
  <id_info>
    <org_study_id>TJ-IRB20210624</org_study_id>
    <nct_id>NCT05028231</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study</brief_title>
  <acronym>NICCE</acronym>
  <official_title>Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy&#xD;
      (PD-1 / PD-L1) combined with chemotherapy for locally advanced thoracic esophageal squamous&#xD;
      cellcarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient will complete 2 cycles of neoadjuvant therapy and decide whether to operate&#xD;
      after evaluating the curative effect if there is no active withdrawal of the subject from the&#xD;
      trial or the researcher believes that the subject is not suitable for further trials. The&#xD;
      patients after operation and without operation enter the survival follow-up period. If the&#xD;
      imaging evaluation is PD after neoadjuvant therapy, the follow-up treatment shall be carried&#xD;
      out according to the following principles: the imaging evaluation belongs to the continuous&#xD;
      operation that can be operated; If the imaging evaluation was inoperable, radical concurrent&#xD;
      radiotherapy and chemotherapy were performed. Postoperative adjuvant therapy shall be&#xD;
      performed according to NCCN guidelines. If it is necessary to improve the local control rate,&#xD;
      postoperative adjuvant radiotherapy is feasible. At the same time, imaging evaluation was&#xD;
      performed until tumor recurrence and metastasis. After tumor recurrence and metastasis, all&#xD;
      patients should also enter survival follow-up; In case of drug withdrawal (such as&#xD;
      intolerable toxicity) other than recurrence and metastasis during treatment, the treatment is&#xD;
      completed, the post-treatment visit is entered, and the survival follow-up is entered after&#xD;
      recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response</measure>
    <time_frame>2-5 years</time_frame>
    <description>According to the detection of pathological specimens after operation, no malignant tumor cells were detected, so the patient achieved complete pathological remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>2-5 years</time_frame>
    <description>The patient achieved CR (complete remission) and still had no probability of recurrence after treatment in 2-years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free-Survival</measure>
    <time_frame>2-5 years</time_frame>
    <description>The time between the beginning of treatment and the observation of disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2-5 years</time_frame>
    <description>The time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Security</measure>
    <time_frame>2-5 years</time_frame>
    <description>The safety of drugs was evaluated from four aspects: adverse events, adverse reactions, serious adverse events and serious adverse reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>2-5 years</time_frame>
    <description>The proportion of patients whose tumor volume reduced to a predetermined value and could maintain the minimum time limit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor markers</measure>
    <time_frame>2-5 years</time_frame>
    <description>Tumor markers refer to those characteristic bioactive substances that can be detected that can reflect the development stage of malignant tumor cells. In a narrow sense, tumor markers refer to bioactive substances synthesized, secreted and released into blood and / or body fluid by malignant tumor cells, including enzymes, hormones, proteins, metabolites and other substances, Their occurrence and changes are closely related to the growth, diffusion, occurrence and development of malignant tumors.</description>
  </other_outcome>
  <other_outcome>
    <measure>Intestinal flora</measure>
    <time_frame>2-5 years</time_frame>
    <description>Intestinal flora homeostasis is called the organ of human body. Intestinal flora homeostasis plays an important role in the life activities of the body. It has important physiological significance in promoting the digestion and absorption of host nutrients, maintaining the normal physiological function of intestine, regulating body immunity and antagonizing the colonization of pathogenic microorganisms.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Neoadjuvant Therapies</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy</intervention_name>
    <description>Each patient will complete 2 cycles of neoadjuvant therapy. After evaluating the curative effect, decide whether to operate or not. Patients with and without surgery enter the survival follow-up period.</description>
    <arm_group_label>Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor tissue samples will be taken before and after treatment for gene testing.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In this clinical trial, patients with resectable thoracic esophageal squamous cell&#xD;
        carcinoma can receive neoadjuvant immunotherapy and neoadjuvant chemotherapy before&#xD;
        operation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-70 Years old，&#xD;
&#xD;
          -  The clinical stage of esophageal cancer confirmed by pathology was cT（1-3）N（1-3）M0&#xD;
&#xD;
          -  No previous chemoradiotherapy&#xD;
&#xD;
          -  ECOG PS: 0-1 points&#xD;
&#xD;
          -  The functions of important organs meet the following requirements (excluding the use&#xD;
             of any blood components and cell growth factors during the screening period)：Absolute&#xD;
             neutrophil count ≥ 1.5 × 109/L； Platelet ≥ 90 × 109/L； Hemoglobin ≥ 9g / dl; Serum&#xD;
             albumin ≥ 3G / dl; Thyroid stimulating hormone (TSH) ≤ ULN (if abnormal, the levels of&#xD;
             T3 and T4 should be investigated at the same time. If the levels of T3 and T4 are&#xD;
             normal, they can be included in the group); Bilirubin ≤ ULN; ALT and AST ≤ 1.5 times&#xD;
             ULN; AKP ≤ 2.5 times ULN; Serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥&#xD;
             60ml / min.&#xD;
&#xD;
          -  Women of childbearing age must have taken reliable contraceptive measures or conducted&#xD;
             pregnancy test (serum or urine) within 7 days before enrollment, and the result is&#xD;
             negative, and are willing to use appropriate contraceptive methods during the test and&#xD;
             8 weeks after the last administration of test drugs. For men, they must agree to use&#xD;
             appropriate methods of contraception or surgical sterilization during the trial and 8&#xD;
             weeks after the last administration of the trial drug.&#xD;
&#xD;
          -  The patients voluntarily joined the study and signed the informed consent form. They&#xD;
             had good compliance and cooperated with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any active autoimmune disease or history of autoimmunity (as follows, but not limited&#xD;
             to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis,&#xD;
             hypophysitis, vasculitis, nephritis, hyperthyroidism and hypothyroidism; Subjects with&#xD;
             vitiligo or asthma in childhood have been completely relieved and do not need any&#xD;
             intervention after adulthood can be included; Asthma in which subjects need&#xD;
             bronchodilators for medical intervention cannot be included).&#xD;
&#xD;
          -  Those who have used other drugs in clinical trials within 4 weeks before the first&#xD;
             medication.&#xD;
&#xD;
          -  Severe allergic reaction to monoclonal antibody.&#xD;
&#xD;
          -  The number of neutrophils in peripheral blood was less than 1500 / mm3.&#xD;
&#xD;
          -  There are cardiac clinical symptoms or diseases that are not well controlled.&#xD;
&#xD;
          -  Previously received radiotherapy, chemotherapy, hormone therapy, surgery or molecular&#xD;
             targeted therapy.&#xD;
&#xD;
          -  The subjects were innate or acquired immunodeficiency (such as HIV), or active&#xD;
             hepatitis (hepatitis B reference: HBsAg) positive, HBVDNA &gt; 2000IU/ml or copy number &gt;&#xD;
             104/ml; Hepatitis C reference: HCV antibody positive.&#xD;
&#xD;
          -  According to the judgment of the researcher, the subject has other factors that may&#xD;
             lead to the forced midway termination of this study, such as other serious diseases&#xD;
             (including mental diseases) requiring combined treatment, serious laboratory&#xD;
             abnormalities, accompanied by family or social factors, which will affect the safety&#xD;
             of the subject, or the collection of data and samples.&#xD;
&#xD;
          -  The researchers judged the patients with high risk of esophageal perforation or no&#xD;
             potential possibility of surgery through endoscopic ultrasonography or imaging.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ni Zhang, Doctor</last_name>
    <phone>+8613006315393</phone>
    <email>zhangnidoc@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Zhang, Doctor</last_name>
    <phone>+8613554081172</phone>
    <email>luzigang@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei Provience</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Wang, Doctor</last_name>
      <phone>+8663639609</phone>
      <email>wangqidoc@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013 Feb 2;381(9864):400-12. doi: 10.1016/S0140-6736(12)60643-6. Review.</citation>
    <PMID>23374478</PMID>
  </reference>
  <reference>
    <citation>Chen MF, Chen PT, Chen WC, Lu MS, Lin PY, Lee KD. The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression. Oncotarget. 2016 Feb 16;7(7):7913-24. doi: 10.18632/oncotarget.6861.</citation>
    <PMID>26761210</PMID>
  </reference>
  <reference>
    <citation>Chen K, Cheng G, Zhang F, Zhang N, Li D, Jin J, Wu J, Ying L, Mao W, Su D. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget. 2016 May 24;7(21):30772-80. doi: 10.18632/oncotarget.8956.</citation>
    <PMID>27120796</PMID>
  </reference>
  <results_reference>
    <citation>Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V; Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011 Jul;12(7):681-92. doi: 10.1016/S1470-2045(11)70142-5. Epub 2011 Jun 16.</citation>
    <PMID>21684205</PMID>
  </results_reference>
  <results_reference>
    <citation>Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 1994 Aug;41(4):391-3.</citation>
    <PMID>7959579</PMID>
  </results_reference>
  <results_reference>
    <citation>Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996 Aug 15;335(7):462-7. Erratum in: N Engl J Med 1999 Jul 29;341(5):384.</citation>
    <PMID>8672151</PMID>
  </results_reference>
  <results_reference>
    <citation>Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001 Jan 15;19(2):305-13.</citation>
    <PMID>11208820</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH, Song HY, Cho KJ, Kim WK, Lee JS, Kim SH, Min YI. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol. 2004 Jun;15(6):947-54.</citation>
    <PMID>15151953</PMID>
  </results_reference>
  <results_reference>
    <citation>Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005 Sep;6(9):659-68.</citation>
    <PMID>16129366</PMID>
  </results_reference>
  <results_reference>
    <citation>Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 1;26(7):1086-92. doi: 10.1200/JCO.2007.12.9593.</citation>
    <PMID>18309943</PMID>
  </results_reference>
  <results_reference>
    <citation>Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.</citation>
    <PMID>26254683</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </results_reference>
  <results_reference>
    <citation>Lim SH, Hong M, Ahn S, Choi YL, Kim KM, Oh D, Ahn YC, Jung SH, Ahn MJ, Park K, Zo JI, Shim YM, Sun JM. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Eur J Cancer. 2016 Jan;52:1-9. doi: 10.1016/j.ejca.2015.09.019. Epub 2015 Nov 26.</citation>
    <PMID>26623522</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang J, Xu B, Mo H, Zhang W, Chen X, Wu D, Qu D, Wang X, Lan B, Yang B, Wang P, Zhang H, Yang Q, Jiao Y. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. Clin Cancer Res. 2018 Mar 15;24(6):1296-1304. doi: 10.1158/1078-0432.CCR-17-2439. Epub 2018 Jan 22.</citation>
    <PMID>29358502</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Ni</investigator_full_name>
    <investigator_title>Proffesor</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

